• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
A female scientist in a laboratory setting
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Patient Perspectives

Lung Cancer: To test or not to test

For patients with lung cancer, biomarker testing may be an option.

By
Susan Mantel
Jun 06, 2016

Each year, 1.8 million people are diagnosed with lung cancer worldwide.¹ In the US alone, someone receives a new diagnosis every two-and-a-half minutes. Still, there are many common misconceptions about this widespread disease.²,³

Did you know that today up to 65% of people with lung cancer do not smoke or are former smokers at the time of their diagnosis?⁴-⁶ Another misconception is that lung cancer is a hopeless disease. While at one time there were few options, in the last dozen years we have made tremendous strides in understanding this complex disease and developing specific treatments for individual patients.

In addition to classifying the disease by how cells look under a microscope, scientists are learning about the molecular changes that enable lung cancer to develop and grow. So far, approximately 60% of patients with adenocarcinoma, a common form of non-small cell lung cancer, have a form of disease linked to these changes or mutations.³ Researchers have identified 12 driver mutations in adenocarcinomas alone, and several others in squamous cell lung cancer.⁷ A few treatments have been approved for three of the known mutations – ALK, EGFR and ROS-1 – and clinical trials are underway for others. To find out whether someone is a candidate for these treatments, a tumor sample needs to be tested for these molecular biomarkers.⁷

Unfortunately, many people who should be tested don’t get this testing at any point in their treatment. Due to inconsistent and confusing language, many aren’t even sure whether their tumor has been tested for these markers. For example, the term “genetic testing” often leads people to think we are discussing whether the lung cancer has been or can be inherited. Furthermore, some people call it “molecular testing,” while others call it “mutation profiling,” “companion diagnostics,” “genomic testing” – the list continues.   

Testing for every actionable mutation is not a standard practice, so initial biopsies often do not get enough tumor sample to be comprehensive. This can result in the need for additional biopsies, as well as in no testing or incomplete testing.⁸ Testing methods also vary by healthcare setting, which can lead to inconsistent results. Each tumor can be tested for one biomarker at a time or for an entire set of biomarkers all at once.⁸

Currently approved targeted therapies almost always stop being effective after some time. We know that in at least some tumors, when this happens, an additional molecular change has taken place. These resistant tumors should be tested again to see if they are a match for a treatment that blocks this new change.⁹,¹º While we have seen that patients are willing to undergo additional biopsies, many doctors have also told us that they are reluctant to put the patient through this.

With so much change happening around understanding and treating lung cancer, a patient’s best bet is to be as informed as possible and to be prepared to discuss a full set of options with his or her healthcare team. More information on lung cancer, biomarker testing and treatment options can be found at www.LUNGevity.org.

Shareline

Learn more about biomarker testing in #lungcancer patients.
Tweet Tweetpopo
Tags: 
Cancer, Disease Awareness, Living With Disease, Oncology, Patient Education, Respiratory, Gene Testing

Susan Mantel

Susan Mantel

is a former Senior Vice President of Research and Education at LUNGevity.

Disclaimer: 

[1] International Cancer Control: Global Cancer Statistics. Centers for Disease Control and Prevention Website. http://www.cdc.gov/cancer/international/statistics.htm. Last updated February 2015.

[2] Jemal A, et al. Global Cancer Statistics. CA Cancer J Clin. 2011;61:69-90.

[3] Estimated New Cancer Cases and Deaths for 2016. SEERCancer Statistics Review 1975-2013. National Cancer Institute, Table 1.1. 
http://seer.cancer.gov/csr/1975_2013/results_single/sect_01_table.01.pdf.

[4] Burns DM. Primary Prevention, Smoking, and Smoking Cessation: Implications for Future Trends in Lung Cancer Prevention. Cancer, 2000. 89:2506-2509.

[5] Thun MJ, et al. Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies. PLOS Medicine, 2008. 5(9): e185.

[6] Park E, Japuntich S, Rigotti N, et al. A Snapshot of Smokers After Lung and Colorectal Cancer Diagnosis. Cancer, June 2012. http://onlinelibrary.wiley.com/doi/10.1002/cncr.26545/abstract.

[7] Lovly C, Horn L, Pao W. 2016. Molecular Profiling of Lung Cancer. My Cancer Genome.https://www.mycancergenome.org/content/disease/lung-cancer/. Updated March 2016.

[8] National Comprehensive Cancer Network, Non-Small Cell Lung Cancer. NCCN Guidelines for Patients: Version 1.2015. 2015; 38.

[9] Targeted Cancer Therapies Fact Sheet. National Cancer Institute Website. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/t.... Last Reviewed: April 2014.

[10] Jekunen A. Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments. Journal of Oncology. January 2015

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Couple looking a digital devices outside
Patient Perspectives

Digital innovation looks set to dominate the 2021 healthcare agenda

A woman, accompanied by her caregiver, shares her experiences with a doctor.
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Chinese family embracing exercise and the outdoors
Patient Perspectives

AI Nurse evolving for health failure patients in China

You are here

  1. Home ›
  2. Stories ›
  3. Patient Perspectives

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.